Format

Send to

Choose Destination
Menopause. 2018 Oct;25(10):1124-1130. doi: 10.1097/GME.0000000000001122.

Efficacy of injecting platelet concentrate combined with hyaluronic acid for the treatment of vulvovaginal atrophy in postmenopausal women with history of breast cancer: a phase 2 pilot study.

Author information

1
Department of Maxillofacial and Plastic & Reconstructive Surgery, Henri Mondor University Hospital, Créteil, France.
2
Henri Mondor Breast Center, Henri Mondor Hospital, Creteil, France.
3
Department of Radiation Oncology, University of Paris East Créteil (UPEC), INSERM U955 EQ 07, Créteil, France.
4
AP-HP, Hospital Henri Mondor, Department of Public Health and Clinical Research Unit (URC Mondor), Créteil cedex, France.
5
Department of Gynecology, Bégin Military Teaching Hospital, Saint Mandé, France.

Abstract

OBJECTIVE:

Approximately 50% to 70% of breast cancer survivors are affected by one or more symptoms of vulvovaginal atrophy (VVA). For those who cannot take hormone therapy, autologous platelet-rich plasma combined with hyaluronic acid (A-PRP-HA) may provide a new alternative therapy for the treatment of VVA in postmenopausal women with history of breast cancer.

METHODS:

We enrolled 20 postmenopausal breast cancers survivors with VVA and a score of <15 on the Gloria Bachman Vaginal Health Index (VHI) comprised of five items including: vaginal pH, elasticity, fluid volume (secretions), epithelial integrity, and moisture.We administered intramucosal injections of A-PRP combined with HA (Regenkit) and performed clinical evaluations at 0, 1, 3, and 6 months. Primary endpoint: evaluation of vulvovaginal mucosa changes using the VHI; secondary endpoint: evaluation of dyspareunia and sexual dysfunction based on the Female Sexual Distress (FSD) score.

RESULTS:

All participants (20 women) showed improvement in the clinical symptoms of vaginal dryness and dyspareunia. The VHI score showed a significant increase at 6 months, going from a total baseline score (pretreatment) of 10.7 ± 2.12 to 20.75 ± 4.8 (P < 0.0001) at 6 months. Improvement in hydration and vaginal epithelial integrity was reported. A VHI score of > 15 showed a successful treatment outcome. The FSD score decreased significantly during the study, from a baseline score of 36.35 ± 2.53 pretreatment to 30.15 ± 2.47 6 months after treatment, representing improvement of 17% (P < 0.0001, respectively). No adverse events were reported.

CONCLUSIONS:

The injection of A-PRP-HA appeared to be a promising method to improve the trophicity and hydration of vaginal mucosa for the treatment of VVA in postmenopausal breast cancer survivors with contraindications to hormone therapy.

PMID:
29738415
DOI:
10.1097/GME.0000000000001122
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center